ArticleInfection and immunity2003
Pulmonary necrosis resulting from DNA vaccination against tuberculosis.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03026972 (A Phase ⅠStudy of the Human Body Tolerance Research of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase ⅠStudy of the Human Body Tolerance Research of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried
Who cites it
44 citing papers in PubMed, 119 citations in OpenAlex.
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.Lancet (London, England) · 2013Trial
- A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults.Frontiers in immunology · 2024Article
- Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease.Frontiers in cellular and infection microbiology · 2023Review
- Immunization withJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- The Pathogenesis of Tuberculosis-The Koch Phenomenon Reinstated.Pathogens (Basel, Switzerland) · 2020Review
- Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.The Journal of infectious diseases · 2019Article
- Tuberculosis and lung damage: from epidemiology to pathophysiology.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs.PloS one · 2017Article
- High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.Frontiers in immunology · 2017Article
- Article
- Permutations of time and place in tuberculosis.The Lancet. Infectious diseases · 2015Review
- Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.Antimicrobial agents and chemotherapy · 2015Article
- Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection.Cold Spring Harbor perspectives in medicine · 2015Review
- Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.Human vaccines & immunotherapeutics · 2014Article
- A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.Clinical and vaccine immunology : CVI · 2013Article
- Heat shock proteins: stimulators of innate and acquired immunity.BioMed research international · 2013Review
- Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.Clinical microbiology reviews · 2012Review
- Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models.Gene therapy · 2012Article
- CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.European journal of immunology · 2012Article
- The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The use of DNA constructs encoding mycobacterial proteins is a promising new approach to vaccination against tuberculosis. A DNA vaccine encoding the hsp60 molecule of Mycobacterium leprae has previously been shown to protect against intravenous infection of mice with Mycobacterium tuberculosis in both the prophylactic and immunotherapeutic modes. It is shown here, however, that this vaccine was not effective in a more realistic aerosol infection model or in a model of latent tuberculosis in the lungs. Moreover, when given in an immunotherapeutic model the immunized mice developed classical Koch reactions characterized by multifocal discrete regions of cellular necrosis throughout the lung granulomas. Similar and equally severe reactions were seen in mice given a vaccine with DNA coding for the Ag85 antigen of M. tuberculosis. This previously unanticipated safety problem indicates that DNA vaccines should be used with caution in individuals who may have already been exposed to tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.